Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

The risk of hepatocellular carcinoma recurrence is universal regardless of the treatment modality applied, and secondary prevention is still an unmet issue even though the elimination of hepatitis C (HCV) with direct antiviral agents (DAAs) was expected to be one of the new options. Unfortunately, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanduzzi-Zamparelli, Marco, Boix, Loreto, Leal, Cassia, Reig, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563506/
https://www.ncbi.nlm.nih.gov/pubmed/31052463
http://dx.doi.org/10.3390/v11050406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563506/
https://www.ncbi.nlm.nih.gov/pubmed/31052463
http://dx.doi.org/10.3390/v11050406

Ejemplares similares